Seed VC · Netherlands
Aglaia invests in oncology drug development companies with a proven ability to select and mature early-stage breakthrough inventions that have the potential to transform cancer treatment. The team has decades of experience in cancer research and brings hands-on involvement in designing R&D plans from early screening through clinical studies.
Business models
biotech_therapeutics
Customer segments
Researchers
Geography
Europe
+ 2 more deals. Score your deck to see the full investment history.
We never publish partner emails directly. Score your deck to unlock contacts for the firms ranked as best-fit.
Aglaia writes first institutional checks where the founder + early product matter more than traction. The seed market is the most dispersed segment of venture; matching to thesis (sector, stage, geography) is where most cold outreach succeeds or fails. VC Boom tracks Aglaia alongside 47,000+ other active investors, ranked weekly by recent-deal momentum, sector concentration, and partner activity.
Seed VC
Arax Capital Partners
DeepTech, Materials, Healthtech
Seed VC
Arboretum Ventures
DeepTech, Healthtech, Biotech
Seed VC
ARCH Venture Partners
DeepTech, Healthtech, Biotech
Seed VC
Archetype Ventures
DeepTech, AI, Industry 4.0 / Robotics
Seed VC
ArchiMed
DeepTech, Healthtech, Biotech
Seed VC
Ardian
DeepTech, AI, Electronics
Drop your pitch. VC Boom scores it on the 8 dimensions VCs read for and ranks the 47,000+ active investors in the database by fit. Aglaia is one of them, and we'll tell you exactly where they sit in your top 100.